AU2020360849A1 - Protein binders to iRhom2 epitopes - Google Patents

Protein binders to iRhom2 epitopes Download PDF

Info

Publication number
AU2020360849A1
AU2020360849A1 AU2020360849A AU2020360849A AU2020360849A1 AU 2020360849 A1 AU2020360849 A1 AU 2020360849A1 AU 2020360849 A AU2020360849 A AU 2020360849A AU 2020360849 A AU2020360849 A AU 2020360849A AU 2020360849 A1 AU2020360849 A1 AU 2020360849A1
Authority
AU
Australia
Prior art keywords
hir2
dko
mef
irhom2
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020360849A
Other languages
English (en)
Inventor
Carl Blobel
Jens Ruhe
Matthias Schneider
Kerstin Selle
Gisela Weskamp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scirhom GmbH
New York Society for Relief of Ruptured and Crippled
Original Assignee
Scirhom GmbH
New York Society for Relief of Ruptured and Crippled
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scirhom GmbH, New York Society for Relief of Ruptured and Crippled filed Critical Scirhom GmbH
Publication of AU2020360849A1 publication Critical patent/AU2020360849A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2020360849A 2019-09-30 2020-09-30 Protein binders to iRhom2 epitopes Pending AU2020360849A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19200589 2019-09-30
EP19200589.0 2019-09-30
PCT/EP2020/077346 WO2021064009A1 (en) 2019-09-30 2020-09-30 Protein binders to irhom2 epitopes

Publications (1)

Publication Number Publication Date
AU2020360849A1 true AU2020360849A1 (en) 2022-04-14

Family

ID=68104520

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020360849A Pending AU2020360849A1 (en) 2019-09-30 2020-09-30 Protein binders to iRhom2 epitopes

Country Status (7)

Country Link
US (1) US20240287172A1 (https=)
EP (1) EP4037699A1 (https=)
JP (2) JP2022550390A (https=)
CN (1) CN115151270A (https=)
AU (1) AU2020360849A1 (https=)
CA (1) CA3151450A1 (https=)
WO (1) WO2021064009A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024510415A (ja) 2021-03-01 2024-03-07 スキロム ゲゼルシャフト ミット ベシュレンクテル ハフツング ｉＲｈｏｍ２に対するヒト化抗体
US20240174744A1 (en) * 2021-03-29 2024-05-30 Scirhom Gmbh Methods of treatment using protein binders to irhom2 epitopes

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
WO2003073843A2 (en) 2002-03-05 2003-09-12 Artemis Pharmaceuticals Gmbh Inbred embryonic stem-cell derived mice
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
WO2014043223A1 (en) * 2012-09-11 2014-03-20 Hospital For Special Surgery Irhom2 inhibition for the treatment of complement mediated disorders
KR20150056788A (ko) 2012-09-19 2015-05-27 애브비 바이오테라퓨틱스 인크. 면역원성이 감소된 항체의 동정 방법
US10024844B2 (en) * 2012-12-20 2018-07-17 Hospital For Special Surgery Identification of an inhibitor of iRhom1 or an inhibitor of iRhom2
CN106471130A (zh) * 2014-05-09 2017-03-01 杰克逊实验室 鉴定改变iRhom多肽活性的化合物的方法及其用途
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CN109045056A (zh) * 2018-07-04 2018-12-21 重庆第二师范学院 多药载药靶向纳米颗粒及其制备方法和应用
CN113993534A (zh) * 2019-04-09 2022-01-28 特殊外科医院 针对iRhom2的蛋白结合物

Also Published As

Publication number Publication date
JP2025179064A (ja) 2025-12-09
CN115151270A (zh) 2022-10-04
US20240287172A1 (en) 2024-08-29
JP2022550390A (ja) 2022-12-01
EP4037699A1 (en) 2022-08-10
WO2021064009A1 (en) 2021-04-08
CA3151450A1 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
CN111744013B (zh) 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合
JP2021184731A (ja) Ｃｄ１２７に対する抗体
CN110914304B (zh) Cd96抗体、其抗原结合片段及医药用途
WO2020020281A1 (zh) 抗tigit抗体及其用途
AU2022252731B2 (en) Protein Binders For iRhom2
JP2025179064A (ja) ｉＲｈｏｍ２エピトープに結合するタンパク質バインダー
US20220411527A1 (en) Compositions and methods for transferrin receptor 1 targeting
CN116554323B (zh) 人源化抗il21抗体的开发和应用
US20240174744A1 (en) Methods of treatment using protein binders to irhom2 epitopes
US12404345B2 (en) Humanized antibodies against iRHOM2
JP7734856B2 (ja) 二重特異性抗体及びその使用
CN118613506A (zh) 一种抗原结合蛋白及其用途
CN117222669A (zh) 针对iRhom2的人源化抗体
EA051567B1 (ru) Гуманизированные антитела против irhom2
CA3133163C (en) Protein binders for irhom2
WO2024179553A1 (zh) 靶向TGFβ的融合蛋白及其应用
CN121736105A (zh) 抗ccr8抗体及其应用
CN118355032A (zh) Bcma抗体及其应用
HK40012331B (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途